GBP510 by SK Bioscience has been clinically approved

The MFDS approved for clinical phase I and II of GBP510, recombinant vaccines such as Novavax

Another COVID-19 vaccine developed by SK Bioscience has been approved for clinical trials in Korea.

 

The MFDS announced on the 31st that it has approved the clinical trial of the domestically developed COVID-19 vaccine GBP510.

 

GBP510 is a vaccine candidate being developed by SK Bioscience and is different from NBP2001, which was clinically approved in November.

 

This clinical trial is to evaluate the safety and immunogenicity of GBP510 in healthy adults, and phase II will be sequentially conducted after phase I.

 

Immunogenicity refers to the rate of increase in neutralizing antibody that eliminates or lowers viral infectivity.

 

GBP510 is a recombinant vaccine made using gene recombination technology of surface antigen protein of COVID-19.

 

The preventive principle is that the surface antigen protein of the vaccine stimulates immune cells to form neutralizing antibodies to induce an immune response, and when COVID-19 invades, the antibody removes COVID-19.

 

SK Bioscience's recombinant vaccine NBP2001, which was approved clinically on the 23rd of last month (Phase I), induces an immune response with the surface antigen protein of COVID-19, and GBP510 is a surface antigen protein that has a nanostructure (icosahedral particle).

 

There is a difference in inducing an immune response by binding to a specific protein that forms.

 

Novavax in USA is conducting phase III clinical trials of a COVID-19 vaccine using genetically modified technology.

 

The MFDS said, "We plan to do our best to ensure that our people can receive treatment opportunities by supporting necessary matters so that a safe and effective COVID-19 treatment and vaccine can be developed quickly."